Phase 1 Castration-resistant Clinical Trials
85 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 85 trials
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled80 locationsNCT06863272
Recruiting
Phase 1
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 1
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen40 enrolled3 locationsNCT07493512
Recruiting
Phase 1
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8+2 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT05398302
Recruiting
Phase 1Phase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Roswell Park Cancer Institute14 enrolled1 locationNCT06305598
Recruiting
Phase 1
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07641049
Recruiting
Phase 1Phase 2
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Pathos AI, Inc.120 enrolled18 locationsNCT06785636
Recruiting
Phase 1
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Metastatic Hormone Sensitive Prostate CancerMetastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 1Phase 2
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.190 enrolled9 locationsNCT07285694
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Advanced Metastatic Castration-resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.84 enrolled22 locationsNCT06609005
Recruiting
Phase 1
Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T
Metastatic Castration-resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital12 enrolled2 locationsNCT07621692
Recruiting
Phase 1
A Phase I Trial of A-CAR032 in Participants With mCRPC
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd.27 enrolled5 locationsNCT07344311
Recruiting
Phase 1Phase 2
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Metastatic Castration-Resistant Prostatic Cancer
T.O.A.D. Oncology SA180 enrolled7 locationsNCT07258407
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals208 enrolled2 locationsNCT07570979
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483